Delaware Peptide Laws

Delaware peptide regulations primarily follow federal law established by the FDA. Like most states, DE does not have specific state-level legislation targeting peptides as a distinct category.

Key Points

• Federal Compliance: All federal FDA regulations apply in Delaware
• Pharmacy Board: The Delaware Board of Pharmacy regulates compounding and dispensing
• Research Use: Peptides sold for research purposes generally follow federal guidelines
• Prescription Requirements: Peptides requiring prescription in federal law require prescription in DE

Regulatory Authority

Peptide-related matters in Delaware fall under multiple regulatory bodies:

• Delaware Board of Pharmacy - Licenses pharmacies and regulates compounding
• Delaware Department of Health - Public health oversight
• FDA - Federal drug approval and enforcement (primary authority)
• DEA - Controlled substance scheduling

Compounding pharmacies in Delaware must comply with both state Board of Pharmacy rules and federal requirements under Sections 503A and 503B of the FD&C Act.

503A Compounding (Traditional)

• Patient-specific prescriptions required
• State Board of Pharmacy licensed
• Limited distribution (not interstate)

503B Outsourcing Facilities

• FDA registered and inspected
• May compound without patient-specific prescriptions
• Subject to Current Good Manufacturing Practice (CGMP)

Enforcement in Delaware typically focuses on:

• Products making unauthorized therapeutic claims
• Sales marketed for human use without proper approval
• Compounding pharmacy compliance
• Consumer protection violations